AIM ImmunoTech highlights DURIPANC trial testing Ampligen plus AstraZeneca’s Imfinzi in metastatic pancreatic cancer maintenance therapy
Bitget2026/10/07 13:14AIM ImmunoTech highlighted a BioTuesdays feature on Ampligen as a maintenance therapy for metastatic pancreatic cancer. Final dosing finished in the DURIPANC trial combining Ampligen with AstraZeneca’s Imfinzi following first-line chemotherapy. Primary and secondary endpoint results have not been presented yet; reporting is pending as the program advances toward pivotal development. The strategy targets immune resistance to sustain disease control, aiming to extend survival and improve quality of life without new chemotherapy. Exploratory observations from a Netherlands named-patient program helped guide biomarker work, though they do not establish efficacy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070914PRIMZONEFULLFEED9841161) on October 07, 2026, and is solely responsible for the information contained therein.
- AIM ImmunoTech highlighted a BioTuesdays feature on Ampligen as a maintenance therapy for metastatic pancreatic cancer.
- Final dosing finished in the DURIPANC trial combining Ampligen with AstraZeneca’s Imfinzi following first-line chemotherapy.
- Primary and secondary endpoint results have not been presented yet; reporting is pending as the program advances toward pivotal development.
- The strategy targets immune resistance to sustain disease control, aiming to extend survival and improve quality of life without new chemotherapy.
- Exploratory observations from a Netherlands named-patient program helped guide biomarker work, though they do not establish efficacy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
